CN113181239A - Oral disinfectant and preparation method thereof - Google Patents
Oral disinfectant and preparation method thereof Download PDFInfo
- Publication number
- CN113181239A CN113181239A CN202110534038.7A CN202110534038A CN113181239A CN 113181239 A CN113181239 A CN 113181239A CN 202110534038 A CN202110534038 A CN 202110534038A CN 113181239 A CN113181239 A CN 113181239A
- Authority
- CN
- China
- Prior art keywords
- deionized water
- amount
- oral disinfectant
- ethanol
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000645 desinfectant Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title abstract description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000008367 deionised water Substances 0.000 claims abstract description 54
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 54
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 29
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 29
- 241000245050 Menispermum Species 0.000 claims abstract description 26
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 24
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 24
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 24
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 24
- 229940013618 stevioside Drugs 0.000 claims abstract description 24
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000019202 steviosides Nutrition 0.000 claims abstract description 24
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 19
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940041616 menthol Drugs 0.000 claims abstract description 19
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 40
- 239000000463 material Substances 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 22
- 238000001914 filtration Methods 0.000 claims description 22
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 20
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000011259 mixed solution Substances 0.000 claims description 12
- 238000004140 cleaning Methods 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 2
- 235000008216 herbs Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 235000015165 citric acid Nutrition 0.000 description 19
- 210000000214 mouth Anatomy 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 11
- 231100000397 ulcer Toxicity 0.000 description 11
- 230000036541 health Effects 0.000 description 8
- 244000052616 bacterial pathogen Species 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000605862 Porphyromonas gingivalis Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 241000606750 Actinobacillus Species 0.000 description 2
- 208000007117 Oral Ulcer Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960003885 sodium benzoate Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an oral disinfectant and a preparation method thereof, belonging to the technical field of sanitary disinfection articles. Solves the technical problems that the oral disinfectant in the prior art is mostly a chemical preparation and has great side effect. The oral disinfectant disclosed by the invention comprises, by 1000mL, 20g of chitosan oligosaccharide, 50g of honeysuckle, 50g of asiatic moonseed rhizome, 0.50g of menthol, 2.5g of citric acid, 7.5g of sodium bicarbonate, 2.0g of stevioside, 2.5g of sodium benzoate and the balance of deionized water. The oral disinfectant has good effect and no toxic or side effect.
Description
Technical Field
The invention belongs to the technical field of sanitary disinfection articles, and particularly relates to an oral cavity disinfectant and a preparation method thereof.
Background
Oral health is closely related to general health. Infection and inflammation factors in the oral cavity can cause or aggravate chronic diseases such as cardiovascular and cerebrovascular diseases, diabetes and the like, harm the health of the whole body and influence the quality of life. Dental caries and periodontal disease destroy tooth hard tissue and supporting tissue around tooth, not only affect chewing, speech, beauty and other functions, but also cause social interaction difficulty and psychological disorder. Oral infections in pregnant women are a risk factor for premature birth and low birth weight infants. The world health organization ranks oral health as one of ten major standards of human health. The standard of oral health is clean teeth, no caries, no pain, normal gum color, and no bleeding.
The focus of oral hygiene is to control bacterial plaque, remove dirt and food residues, enhance physiological stimulation, and provide a clean and healthy environment for the oral cavity and the dental jaw system, thereby exerting the physiological functions and maintaining the oral health.
The oral disinfectant is an article for disinfecting the oral cavity in a mouth rinsing mode, but most of the oral disinfectant in the prior art is chemical agents and has great side effects.
Disclosure of Invention
The invention aims to solve the technical problem that the oral disinfectant in the prior art is mostly a chemical preparation and has great side effects, and provides the oral disinfectant and the preparation method thereof.
The technical scheme adopted by the invention for achieving the purpose is as follows.
The invention provides an oral disinfectant, which comprises 20g of chitosan oligosaccharide, 50g of honeysuckle, 50g of asiatic moonseed rhizome, 0.50g of menthol, 2.5g of citric acid, 7.5g of sodium bicarbonate, 2.0g of stevioside, 2.5g of sodium benzoate and the balance of deionized water, wherein the amount of the deionized water is 1000 mL.
Preferably, the pH value of the oral disinfectant is 6.5-7.8.
Preferably, the oral disinfectant has a relative density of 1.05 to 1.09.
The invention also provides a preparation method of the oral disinfectant, which comprises the following steps:
step one, taking 20g of chitosan oligosaccharide, 50g of honeysuckle, 50g of asiatic moonseed rhizome, 0.50g of menthol, 2.5g of citric acid, 7.5g of sodium bicarbonate, 2.0g of stevioside and 2.5g of sodium benzoate;
step two, cleaning the honeysuckle, adding deionized water for a plurality of times for decoction, combining decoction, filtering, decompressing and compressing the filtrate until the relative density is 1.15(50 ℃), cooling, adding ethanol, stirring uniformly, standing overnight, filtering, decompressing the filtrate to remove the ethanol to obtain honeysuckle extract;
cleaning rhizoma Menispermi, decocting with deionized water for several times, mixing decoctions, filtering, vacuum compressing the filtrate to relative density of 1.15(50 deg.C), cooling, adding ethanol, stirring, standing overnight, filtering, and removing ethanol from the filtrate under reduced pressure to obtain rhizoma Menispermi extractive solution;
step three, mixing the honeysuckle extract and the asiatic moonseed rhizome extract uniformly, adding deionized water to 750mL, then adding menthol, dissolving, adding sodium benzoate, citric acid, chitosan oligosaccharide and stevioside, and stirring until the sodium benzoate, the citric acid, the chitosan oligosaccharide and the stevioside are dissolved to obtain a mixed solution;
step four, dissolving sodium bicarbonate in 250mL of deionized water to obtain a sodium bicarbonate solution;
and step five, uniformly mixing the mixed solution with a sodium bicarbonate solution, and sterilizing to obtain the oral disinfectant.
Preferably, in the second step, the process of adding deionized water for many times for decoction respectively comprises: adding deionized water in an amount which is 8 times of the amount of the medicinal materials, decocting for 40 minutes, adding deionized water in an amount which is 7 times of the amount of the medicinal materials, decocting for 30 minutes, and finally adding deionized water in an amount which is 6 times of the amount of the medicinal materials, and decocting for 20 minutes.
Preferably, in the second step, the amount of ethanol is 3 times of the amount of the medicinal materials, the concentration of ethanol is 95%, and after the ethanol is added, the ethanol content of the solution is 70%.
Preferably, the step five further comprises subpackaging and sealing before autoclaving.
Compared with the prior art, the invention has the beneficial effects that:
the oral disinfectant has good effect and no toxic or side effect.
Detailed Description
For a further understanding of the invention, reference will now be made to the preferred embodiments of the invention, but it is to be understood that the description is intended to illustrate further features and advantages of the invention, and not to limit the scope of the claims.
The oral disinfectant disclosed by the invention comprises, by 1000mL, 20g of chitosan oligosaccharide, 50g of honeysuckle, 50g of asiatic moonseed rhizome, 0.50g of menthol, 2.5g of citric acid, 7.5g of sodium bicarbonate, 2.0g of stevioside, 2.5g of sodium benzoate and the balance of deionized water.
In the technical scheme, the pH value of the oral disinfectant is preferably 6.5-7.8.
In the technical scheme, the relative density of the oral disinfectant is preferably 1.05-1.09.
The preparation method of the oral disinfectant disclosed by the invention comprises the following steps of:
step one, taking 20g of chitosan oligosaccharide, 50g of honeysuckle, 50g of asiatic moonseed rhizome, 0.50g of menthol, 2.5g of citric acid, 7.5g of sodium bicarbonate, 2.0g of stevioside and 2.5g of sodium benzoate;
step two, cleaning the honeysuckle, adding deionized water for a plurality of times for decoction, combining decoction, filtering, decompressing and compressing the filtrate until the relative density is 1.15(50 ℃), cooling, adding ethanol, stirring uniformly, standing overnight, filtering, decompressing the filtrate to remove the ethanol to obtain honeysuckle extract;
cleaning rhizoma Menispermi, decocting with deionized water for several times, mixing decoctions, filtering, vacuum compressing the filtrate to relative density of 1.15(50 deg.C), cooling, adding ethanol, stirring, standing overnight, filtering, and removing ethanol from the filtrate under reduced pressure to obtain rhizoma Menispermi extractive solution;
step three, mixing the honeysuckle extract and the asiatic moonseed rhizome extract uniformly, adding deionized water to 750mL, then adding menthol, dissolving, adding sodium benzoate, citric acid, chitosan oligosaccharide and stevioside, and stirring until the sodium benzoate, the citric acid, the chitosan oligosaccharide and the stevioside are dissolved to obtain a mixed solution;
step four, dissolving sodium bicarbonate in 250mL of deionized water to obtain a sodium bicarbonate solution;
and step five, uniformly mixing the mixed solution with a sodium bicarbonate solution, and sterilizing to obtain the oral disinfectant.
In the above technical scheme, in the second step, the process of adding deionized water for multiple times for decoction respectively comprises: adding deionized water in an amount which is 8 times of the amount of the medicinal materials, decocting for 40 minutes, adding deionized water in an amount which is 7 times of the amount of the medicinal materials, decocting for 30 minutes, and finally adding deionized water in an amount which is 6 times of the amount of the medicinal materials, and decocting for 20 minutes.
In the technical scheme, in the second step, the amount of the ethanol is 3 times of the amount of the medicinal materials, the concentration of the ethanol is 95%, and after the ethanol is added, the ethanol content of the solution is 70%.
In the above technical scheme, step five, still include partial shipment, closing cap before autoclaving.
In the above technical scheme, in the fifth step, high-pressure sterilization is adopted for sterilization.
The oral disinfectant disclosed by the invention has the following principle:
1. the chitosan oligosaccharide is formed by connecting 2-20 glucosamine through beta-1, 4-glycosidic bonds. The molecular weight is about 2000, and the product is easily dissolved in water and most easily absorbed by human body. The amino group contained in the molecular structure of the chitosan oligosaccharide is alkaline, so that the pH value of body fluid can be increased, and the growth of bacteria can be inhibited. It can inhibit severe damage of tissues and organs caused by over-activation of neutrophils. The chitosan oligosaccharide has bidirectional regulation effect on macrophages: firstly, the chitosan oligosaccharide can activate macrophages in a resting state, and enhance the migration activity of the macrophages and the capability of phagocytosing bacteria; secondly, the chitosan oligosaccharide plays an anti-inflammatory role through the combination with related proteins; and the chitosan oligosaccharide has a broad-spectrum antibacterial effect, can inhibit the growth of most bacteria such as escherichia coli, salmonella, porphyromonas gingivalis, actinobacillus, staphylococcus aureus, streptococcus and the like, and particularly has a very obvious antibacterial effect on staphylococcus aureus.
2. The honeysuckle contains chlorogenic acid and other active ingredients, has strong inhibiting effect on streptococcus, staphylococcus aureus, porphyromonas gingivalis, actinobacillus and the like, and also has the effects of relieving pain and promoting wound healing.
3. Rhizoma Menispermi has effects of clearing heat and detoxicating, relieving sore throat and eliminating swelling, and has adjuvant treatment effect on oral ulcer, periodontitis, gingivitis, etc.
4. The chitosan oligosaccharide, the honeysuckle and the asiatic moonseed rhizome are jointly used in the oral disinfectant, and have the effects of mutual supplement and promotion.
The terms used in the present invention generally have meanings commonly understood by those of ordinary skill in the art, unless otherwise specified. In order to make those skilled in the art better understand the technical solution of the present invention, the present invention will be further described in detail with reference to the following embodiments.
In the following examples, various procedures and methods not described in detail are conventional methods well known in the art. Materials, reagents, devices, instruments, apparatuses and the like used in the following examples are commercially available unless otherwise specified.
Comparative example 1
The oral disinfectant comprises, by 1000mL, honeysuckle (six groups, blank group 0g, group a 6.25g, group b 12.5g, group c 25g, group d 50g, group e 100g), asiatic moonseed 50g, menthol 0.50g, citric acid 2.5g, sodium bicarbonate 7.5g, stevioside 2.0g, sodium benzoate 2.5g, and the balance deionized water.
The preparation method of the oral disinfectant comprises the following steps:
step one, taking honeysuckle, asiatic moonseed rhizome, menthol, citric acid, sodium bicarbonate, stevioside and sodium benzoate according to the composition and the mixture ratio;
step two, cleaning honeysuckle, firstly adding deionized water which is 8 times of the amount of the medicinal materials, decocting for 40 minutes, then adding deionized water which is 7 times of the amount of the medicinal materials, decocting for 30 minutes, finally adding deionized water which is 6 times of the amount of the medicinal materials, decocting for 20 minutes, combining decoction, filtering, decompressing and compressing filtrate until the relative density is 1.15(50 ℃), cooling, adding 95% ethanol which is 3 times of the amount of the medicinal materials, uniformly stirring, standing overnight, filtering, decompressing the filtrate to remove the ethanol, and obtaining honeysuckle extract;
cleaning Asiatic moonseed rhizome, firstly adding deionized water which is 8 times of the amount of the medicinal materials, decocting for 40 minutes, then adding deionized water which is 7 times of the amount of the medicinal materials, decocting for 30 minutes, finally adding deionized water which is 6 times of the amount of the medicinal materials, decocting for 20 minutes, combining decoction liquids, filtering, decompressing and compressing filtrate until the relative density is 1.15(50 ℃), cooling, adding 95% ethanol which is 3 times of the amount of the medicinal materials, uniformly stirring, standing overnight, filtering, decompressing the filtrate to remove the ethanol, and obtaining Asiatic moonseed rhizome extract;
step three, mixing the honeysuckle extract and the asiatic moonseed rhizome extract uniformly, adding deionized water to 750mL, then adding menthol, adding sodium benzoate, citric acid and stevioside after dissolving, and stirring until dissolving to obtain a mixed solution;
step four, dissolving sodium bicarbonate in 250mL of deionized water to obtain a sodium bicarbonate solution;
and step five, uniformly mixing the mixed solution with a sodium bicarbonate solution, and sterilizing to obtain the oral disinfectant.
The oral disinfectant of comparative example 1 is taken to treat 3 pathogenic bacteria in the oral cavity: streptococcus mutans, Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans were subjected to bacteriostatic experiments, and the results are shown in Table 1.
TABLE 1 oral disinfectant of comparative example 1 having antibacterial effect on common pathogenic bacteria in oral cavity
Comparative example 2
The oral disinfectant comprises, by 1000mL, chitosan oligosaccharide (six groups, blank group 0g, a1 group 2.5g, b1 group 5.0g, c1 group 10g, d1 group 20g, e1 group 40g), asiatic moonseed rhizome 50g, menthol 0.50g, citric acid 2.5g, sodium bicarbonate 7.5g, stevioside 2.0g, sodium benzoate 2.5g, and the balance of deionized water.
The preparation method of the oral disinfectant comprises the following steps:
step one, taking chitosan oligosaccharide, asiatic moonseed rhizome, menthol, citric acid, sodium bicarbonate, stevioside and sodium benzoate according to the composition and the mixture ratio;
step two, cleaning the Asiatic moonseed rhizome, firstly adding deionized water which is 8 times of the amount of the medicinal materials, decocting for 40 minutes, then adding deionized water which is 7 times of the amount of the medicinal materials, decocting for 30 minutes, finally adding deionized water which is 6 times of the amount of the medicinal materials, decocting for 20 minutes, combining the decoction solutions, filtering, decompressing and compressing the filtrate until the relative density is 1.15(50 ℃), cooling, adding 95% ethanol which is 3 times of the amount of the medicinal materials, uniformly stirring, standing overnight, filtering, decompressing the filtrate to remove the ethanol, and obtaining an Asiatic moonseed rhizome extracting solution;
step three, adding deionized water to the Asiatic moonseed rhizome extract to 750mL, then adding menthol, dissolving, adding sodium benzoate, citric acid, chitosan oligosaccharide and stevioside, and stirring until the sodium benzoate, the citric acid, the chitosan oligosaccharide and the stevioside are dissolved to obtain a mixed solution;
step four, dissolving sodium bicarbonate in 250mL of deionized water to obtain a sodium bicarbonate solution;
and step five, uniformly mixing the mixed solution with a sodium bicarbonate solution, and sterilizing to obtain the oral disinfectant.
The oral disinfectant of comparative example 2 is taken to treat 3 pathogenic bacteria in the oral cavity: streptococcus mutans, Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans were subjected to bacteriostatic experiments, and the results are shown in Table 2.
TABLE 2 oral disinfectant of comparative example 2 with bacteriostatic rate against common pathogenic bacteria in oral cavity
Example 1
The oral disinfectant comprises, by 1000mL, 20g of chitosan oligosaccharide, 50g of honeysuckle, 50g of asiatic moonseed rhizome, 0.50g of menthol, 2.5g of citric acid, 7.5g of sodium bicarbonate, 2.0g of stevioside, 2.5g of sodium benzoate and the balance of deionized water.
The invention also provides a preparation method of the oral disinfectant, which comprises the following steps:
step one, taking 20g of chitosan oligosaccharide, 50g of honeysuckle, 50g of asiatic moonseed rhizome, 0.50g of menthol, 2.5g of citric acid, 7.5g of sodium bicarbonate, 2.0g of stevioside and 2.5g of sodium benzoate;
step two, cleaning honeysuckle, firstly adding deionized water which is 8 times of the amount of the medicinal materials, decocting for 40 minutes, then adding deionized water which is 7 times of the amount of the medicinal materials, decocting for 30 minutes, finally adding deionized water which is 6 times of the amount of the medicinal materials, decocting for 20 minutes, combining decoction, filtering, decompressing and compressing filtrate until the relative density is 1.15(50 ℃), cooling, adding 95% ethanol which is 3 times of the amount of the medicinal materials, uniformly stirring, standing overnight, filtering, decompressing the filtrate to remove the ethanol, and obtaining honeysuckle extract;
cleaning Asiatic moonseed rhizome, firstly adding deionized water which is 8 times of the amount of the medicinal materials, decocting for 40 minutes, then adding deionized water which is 7 times of the amount of the medicinal materials, decocting for 30 minutes, finally adding deionized water which is 6 times of the amount of the medicinal materials, decocting for 20 minutes, combining decoction liquids, filtering, decompressing and compressing filtrate until the relative density is 1.15(50 ℃), cooling, adding 95% ethanol which is 3 times of the amount of the medicinal materials, uniformly stirring, standing overnight, filtering, decompressing the filtrate to remove the ethanol, and obtaining Asiatic moonseed rhizome extract;
step three, mixing the honeysuckle extract and the asiatic moonseed rhizome extract uniformly, adding deionized water to 750mL, then adding menthol, dissolving, adding sodium benzoate, citric acid, chitosan oligosaccharide and stevioside, and stirring until the sodium benzoate, the citric acid, the chitosan oligosaccharide and the stevioside are dissolved to obtain a mixed solution;
dissolving sodium bicarbonate in deionized water to obtain a sodium bicarbonate solution;
and step five, uniformly mixing the mixed solution with a sodium bicarbonate solution, and sterilizing to obtain the oral disinfectant.
1. The oral disinfectant of example 1 is taken to treat 3 pathogenic bacteria in the oral cavity: streptococcus mutans, Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans were subjected to bacteriostatic experiments, and the results are shown in Table 3.
Table 3 bacteriostasis rate of oral disinfectant of example 1 to common oral pathogenic bacteria
As can be seen from Table 3, the chitosan oligosaccharide and the decoction of honeysuckle can improve the bacteriostasis rate.
2. Preventing and treating oral ulcer
Pathological modeling and administration method: firstly, a surgical forceps with a soft rubber pipe sleeve is used for prying open the mouth of a rat, the tongue is slightly pulled out by another forceps, a round filter paper sheet soaked with 100% acetic acid solution and 6mm in thickness is placed on the tongue surface to turn white, then redness and swelling occur, and ulcer begins to appear after acute inflammatory reaction of heat pain occurs for one day. After pathology 50 rats were randomly divided into five groups of 10 rats each. The first group was a control group, which was not dosed after molding, and 3 ml/one of distilled water was administered to rinse the tongue surface three times a day. The second group is prepared by rinsing the tongue surface with clotrimazole gargle (per 500 ml containing chlorhexidine gluconate 0.6 g, metronidazole 0.1 g, glycerol 25 ml, and concentrated peppermint water 5 ml) 3 ml/piece three times per day. The third, fourth and fifth groups are used for washing the tongue surface with the oral disinfectant of the embodiment 1 three times a day, and the dosage is 1 ml/piece (low dosage), 2 ml/piece (medium dosage) and 3 ml/piece (high dosage), and the tongue surface is washed and administered for one week. The results of the experiment are shown in table 4.
The experimental results show that: after the tongue of the animal is subjected to chemical corrosion to cause acute inflammation, the animal can not eat at the beginning, the oral disinfectant solution group in the embodiment 1 can eat after the tongue surface of the animal is flushed for the third day for two days, meanwhile, the swelling of the modeling ulcer surface is seen to subside, the ulcer begins to shrink after the flushing for the fourth day, the appetite is gradually recovered, and the tongue surface ulcer of the animal begins to disappear after the seventh day. The experimental control group (with tongue surface flushed with distilled water) had no food until the fifth day, and had a much larger area of ulcer surface than the oral disinfectant group of example 1. The koutai gargle can be eaten in the fourth day, and the animal tongue surface ulcer begins to disappear after one week. The results show that the oral disinfectant of the example 1 has obvious functions of diminishing inflammation and promoting ulcer healing, so that the ulcer on the tongue surface is obviously reduced, and the oral disinfectant is obviously different from a control group. Experiments also prove that the oral disinfectant in example 1 has no stimulation effect on oral cavity.
The results of the pharmacodynamic tests are shown in table 4.
TABLE 4 Effect of the oral disinfectant of example 1 on healing of ulcers on the lingual surface of rats
As can be seen from Table 4, the oral disinfectant of example 1 has a significant difference from the experimental control group, and has a significant effect of promoting the healing of the ulcer surface. The oral disinfectant of example 1 is superior to the positive koutou gargle in promoting healing of ulcer surfaces, compared to the koutou gargle.
3. The pH of the three samples was measured to be between 6.5 and 7.8 according to the pH measurement method in the Chinese pharmacopoeia (2020 edition).
4. The relative density of three samples is measured to be 1.05-1.09 according to the relative density measuring method in Chinese pharmacopoeia (2020 edition).
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (7)
1. An oral disinfectant is characterized by comprising 20g of chitosan oligosaccharide, 50g of honeysuckle, 50g of asiatic moonseed rhizome, 0.50g of menthol, 2.5g of citric acid, 7.5g of sodium bicarbonate, 2.0g of stevioside, 2.5g of sodium benzoate and the balance of deionized water, wherein the amount of the deionized water is 1000 mL.
2. The oral disinfectant of claim 1, wherein the pH of the oral disinfectant is between 6.5 and 7.8.
3. The oral disinfectant of claim 1, wherein the relative density of the oral disinfectant is 1.05-1.09.
4. The method for preparing an oral disinfectant according to any one of claims 1 to 3, comprising the steps of:
step one, taking 20g of chitosan oligosaccharide, 50g of honeysuckle, 50g of asiatic moonseed rhizome, 0.50g of menthol, 2.5g of citric acid, 7.5g of sodium bicarbonate, 2.0g of stevioside and 2.5g of sodium benzoate;
step two, cleaning the honeysuckle, adding deionized water for a plurality of times for decoction, combining decoction, filtering, decompressing and compressing the filtrate until the relative density is 1.15, cooling, adding ethanol, stirring uniformly, standing overnight, filtering, decompressing the filtrate to remove the ethanol to obtain honeysuckle extract;
cleaning rhizoma Menispermi, decocting with deionized water for several times, mixing decoctions, filtering, vacuum compressing the filtrate to relative density of 1.15, cooling, adding ethanol, stirring, standing overnight, filtering, and removing ethanol from the filtrate under reduced pressure to obtain rhizoma Menispermi extractive solution;
step three, mixing the honeysuckle extract and the asiatic moonseed rhizome extract uniformly, adding deionized water to 750mL, then adding menthol, dissolving, adding sodium benzoate, citric acid, chitosan oligosaccharide and stevioside, and stirring until the sodium benzoate, the citric acid, the chitosan oligosaccharide and the stevioside are dissolved to obtain a mixed solution;
step four, dissolving sodium bicarbonate in 250mL of deionized water to obtain a sodium bicarbonate solution;
and step five, uniformly mixing the mixed solution with a sodium bicarbonate solution, and sterilizing to obtain the oral disinfectant.
5. The method for preparing oral disinfectant according to claim 4, wherein in the second step, the processes of adding deionized water and decocting for multiple times respectively comprise: adding deionized water in an amount which is 8 times of the amount of the medicinal materials, decocting for 40 minutes, adding deionized water in an amount which is 7 times of the amount of the medicinal materials, decocting for 30 minutes, and finally adding deionized water in an amount which is 6 times of the amount of the medicinal materials, and decocting for 20 minutes.
6. The method for preparing oral disinfectant according to claim 4, wherein in the second step, the amount of ethanol is 3 times of the amount of the herbs, the concentration of ethanol is 95%, and the ethanol content of the solution after adding ethanol is 70%.
7. The method for preparing oral disinfectant as recited in claim 4, further comprising the step five of dispensing and sealing before autoclaving.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110534038.7A CN113181239A (en) | 2021-05-17 | 2021-05-17 | Oral disinfectant and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110534038.7A CN113181239A (en) | 2021-05-17 | 2021-05-17 | Oral disinfectant and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113181239A true CN113181239A (en) | 2021-07-30 |
Family
ID=76982024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110534038.7A Withdrawn CN113181239A (en) | 2021-05-17 | 2021-05-17 | Oral disinfectant and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113181239A (en) |
-
2021
- 2021-05-17 CN CN202110534038.7A patent/CN113181239A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH05503280A (en) | Topical preparations for the treatment of conditions of teeth and their supporting tissues | |
| EA018425B1 (en) | Pharmaceutical, disinfectant or preservation extract of trigonella foenum-graecum, method for preparing and use thereof | |
| RU2381021C2 (en) | Liposome containing tooth paste | |
| RU2699560C1 (en) | Dental gel with a phytopeloid composition | |
| CN108324739B (en) | Pharmaceutical composition and application thereof, oral cleaning and nursing product, oral health product and medicine | |
| WO2014196947A1 (en) | Multifunctional toothpaste | |
| KR20170141053A (en) | Composition for prevention or treatment of dental disease comprising an extract of Gardenia jasminoides | |
| KR20160088841A (en) | Composition for preventing or treating oral disease comprising Emodin | |
| CN112426376A (en) | Mouthwash and preparation method thereof | |
| KR20170141034A (en) | Composition for prevention or treatment of dental disease comprising Panax ginseng extract | |
| US10813878B2 (en) | Oral health composition | |
| CN113181239A (en) | Oral disinfectant and preparation method thereof | |
| CN114028327B (en) | Oral traditional Chinese medicine antibacterial gel containing ectoin and strontium chloride and preparation and application methods thereof | |
| KR102553374B1 (en) | Composition for prevention or treatment of dental disease comprising cistanoside A | |
| KR101596438B1 (en) | Composition for preventing or treating oral disease comprising Glabridin | |
| RU2813879C1 (en) | Anti-inflammatory composition (versions) for local application in oral cavity and upper respiratory tract | |
| RU2618889C1 (en) | Mouthwash agent having antiinflammatory, antimicrobial, wound-healing effect | |
| KR101630829B1 (en) | Composition for preventing or treating oral disease comprising Echinacoside | |
| CN109512683A (en) | A kind of povidone iodine composition and the preparation method and application thereof | |
| RU2810839C1 (en) | Use of infusion of multicomponent collection of medicinal plants for mouth rinsing to prevent development and treatment of mucositis | |
| CN113876657B (en) | Application of cercis chinensis flower extract in oral care products | |
| RU2822421C1 (en) | Composition of active dental base for oral care products, stimulating restorative and reparative processes in oral cavity tissues, and composition for oral hygiene based thereon (versions) | |
| RU2090183C1 (en) | Medical protection tooth paste | |
| KR102132873B1 (en) | Composition for the prevention or treating of oral diseases comprising extract of indigo, Lindera Root, Madder Root and Psoraleae Semen | |
| JP2002322075A (en) | Composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210730 |